13 results on '"Hiemenz, J.W."'
Search Results
2. Patient-Reported Quality of Life and Goals of Care in the Treatment of Locally Advanced Non–small Cell Lung Cancer
- Author
-
Hitchcock, K., primary, Rausch-Osian, S.M., additional, Kules, S., additional, King, J., additional, Sierra, A., additional, Hiemenz, J.W., additional, Ohlendorf, J., additional, Minton, J., additional, Marshall, K., additional, and Hoppe, B.S., additional more...
- Published
- 2017
- Full Text
- View/download PDF
Catalog
3. Clinical Research In The Lay Press: Irresponsible Journalism Raises A Huge Dose Of Doubt
- Author
-
Anaissie, E.J, Segal, B.H, Graybill, J.R, Arndt, C, Perfect, J.R, Kleinberg, M, Pappas, P, Benjamin, D, Rubin, R, Aberg, J.A, Adderson, E.E, Adler-Shohet, F.C, Akan, H, Akova, M, Almyroudis, N.G, Alexander, B.D, Andes, D, Arrieta, A, Baddley, J.W, Barron, M.A, Belzberg, H, Boucher, H.W, Boyce, T.G, Casadevall, A, Chandrasekar, P.H, Cleary, J.D, Cordonnier, C, Cornely, O.A, Cuenca-Estrella, M, Daly, J.S, Daoura, N, Denning, D.W, DePauw, B, De Repentigny, L, Dignani, M.C, Dismukes, W.E, Donnelly, J.P, Donowitz, G.R, Dupont, B, Drusano, G, Ellis, M, Espinel-Ingroff, A, Fishman, J.A, Fleming, R, Forrest, G, Ghannoum, M, Goldman, M, Grazziutti, M, Greene, J.H, Greenberg, R.N, Gubbins, P.O, Hadley, S, Herbrecht, R, Hiemenz, J.W, Hope, W, Hospenthal, D.R, Husain, S, Ito, J.I, Jacobson, R.M, Johnson, M, Keating, M.R, Kett, D.H, Knapp, K, Kontoyiannis, D.P, Krcmery, V.C, Larsen, R, Laverdiere, M, Ljungman, P, Lortholary, O, Maertens, J, Marriott, D, Mattiuzzi, G, McGinnis, M.R, Morris, M, Nucci, M, Odds, F.C, Pankey, G.A, Patterson, T, Pfaller, M, Razonable, R.R, Reboli, A.C, Rinaldi, M.G, Roberts, G.D, Rodriguez Tudela, J.L, Rotstein, C, Ruhnke, M, Schuster, M, Shoham, S, Sia, I.G, Siebel, N, Silviera, F, Singh, N, Sobel, J, Solomkin, J.S, Sorrell, T.C, Steinbach, W.J, Temesgen, Z, Tortorano, A, Vartivarian, S, Verweij, P, Viscoli, C, Viviani, M.A, Walker, R.C, Wheat, J.L, Wiley, J, Williamson, P, Wingard, J.R, Yu, V.L, Zaoutis, T., and İç Hastalıkları more...
- Published
- 2006
4. Aztreonam for febrile neutropenia in patients with beta‐lactam allergy
- Author
-
McCullough, B.J., primary, Wiggins, L.E., additional, Richards, A., additional, Klinker, K., additional, Hiemenz, J.W., additional, and Wingard, J.R., additional
- Published
- 2013
- Full Text
- View/download PDF
5. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.
- Author
-
Anaissie, E., Segal, B.H., Graybill, J.R., Arndt, C., Perfect, J.R., Kleinberg, M., Pappas, P.G., Benjamin, D., Rubin, R., Aberg, J.A., Adderson, E.E., Adler-Shohet, F.C., Akan, H., Akova, M., Almyroudis, N.G., Alexander, B.D., Andes, D., Arrieta, A., Baddley, J.W., Barron, M.A., Belzberg, H., Boucher, H.W., Boyce, T.G., Casadevall, A., Chandrasekar, P.H., Cleary, J.D., Cordonnier, C., Cornely, O.A., Cuenca-Estrella, M., Daly, J.S., Daoura, N., Denning, D.W., Pauw, B.E. de, Repentigny, L. de, Dignani, M.C., Dismukes, W.E., Donnelly, J.P., Donowitz, G., Dupont, B., Drusano, G., Ellis, M., Espinel-Ingroff, A., Fishman, J.A., Fleming, R., Forrest, G., Ghannoum, M.A., Goldman, M, Grazziutti, M., Greene, J.N., Greenberg, R.N., Gubbins, P.O., Hadley, S., Herbrecht, R., Hiemenz, J.W., Hope, W., Hospenthal, D.R., Husain, S., Ito, J.I., Jacobson, R.M., Johnson, M., Keating, M.R., Kett, D.H., Knapp, K., Kontoyiannis, D.P., Krcmery, V., Larsen, R., Laverdiere, M., Ljungman, P., Lortholary, O., Maertens, J., Marriott, D., Mattiuzzi, G., McGinnis, M.R., Morris, M., Nucci, M., Odds, F.C., Pankey, G.A., Patterson, T., Pfaller, M., Razonable, R.R., Reboli, A.C., Rinaldi, M.G., Roberts, G.D., Rodriguez-Tudela, J.L., Rotstein, C., Ruhnke, M., Schuster, M., Shoham, S., Sia, I.G., Siebel, N., Silviera, F, Singh, N., Sobel, J., Solomkin, J.S., Sorrell, T.C., Steinbach, W.J., Temesgen, Z., Tortorano, A., Vartivarian, S., Anaissie, E., Segal, B.H., Graybill, J.R., Arndt, C., Perfect, J.R., Kleinberg, M., Pappas, P.G., Benjamin, D., Rubin, R., Aberg, J.A., Adderson, E.E., Adler-Shohet, F.C., Akan, H., Akova, M., Almyroudis, N.G., Alexander, B.D., Andes, D., Arrieta, A., Baddley, J.W., Barron, M.A., Belzberg, H., Boucher, H.W., Boyce, T.G., Casadevall, A., Chandrasekar, P.H., Cleary, J.D., Cordonnier, C., Cornely, O.A., Cuenca-Estrella, M., Daly, J.S., Daoura, N., Denning, D.W., Pauw, B.E. de, Repentigny, L. de, Dignani, M.C., Dismukes, W.E., Donnelly, J.P., Donowitz, G., Dupont, B., Drusano, G., Ellis, M., Espinel-Ingroff, A., Fishman, J.A., Fleming, R., Forrest, G., Ghannoum, M.A., Goldman, M, Grazziutti, M., Greene, J.N., Greenberg, R.N., Gubbins, P.O., Hadley, S., Herbrecht, R., Hiemenz, J.W., Hope, W., Hospenthal, D.R., Husain, S., Ito, J.I., Jacobson, R.M., Johnson, M., Keating, M.R., Kett, D.H., Knapp, K., Kontoyiannis, D.P., Krcmery, V., Larsen, R., Laverdiere, M., Ljungman, P., Lortholary, O., Maertens, J., Marriott, D., Mattiuzzi, G., McGinnis, M.R., Morris, M., Nucci, M., Odds, F.C., Pankey, G.A., Patterson, T., Pfaller, M., Razonable, R.R., Reboli, A.C., Rinaldi, M.G., Roberts, G.D., Rodriguez-Tudela, J.L., Rotstein, C., Ruhnke, M., Schuster, M., Shoham, S., Sia, I.G., Siebel, N., Silviera, F, Singh, N., Sobel, J., Solomkin, J.S., Sorrell, T.C., Steinbach, W.J., Temesgen, Z., Tortorano, A., and Vartivarian, S. more...
- Abstract
Contains fulltext : 50792.pdf (publisher's version ) (Open Access)
- Published
- 2006
6. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses.
- Author
-
Rex, J.H., Walsh, T.J., Nettleman, M., Anaissie, E., Bennett, J.E., Bow, E.J., Carillo-Munoz, A.J., Chavanet, P., Cloud, G.A., Denning, D.W., Pauw, B.E. de, Edwards, J.E., Hiemenz, J.W., Kauffman, C.A., Lopez-Berestein, G., Martino, P., Sobel, J.D., Stevens, D.A., Sylvester, R.J., Tollemar, J., Viscoli, C., Viviani, M.A., Wu, T., Rex, J.H., Walsh, T.J., Nettleman, M., Anaissie, E., Bennett, J.E., Bow, E.J., Carillo-Munoz, A.J., Chavanet, P., Cloud, G.A., Denning, D.W., Pauw, B.E. de, Edwards, J.E., Hiemenz, J.W., Kauffman, C.A., Lopez-Berestein, G., Martino, P., Sobel, J.D., Stevens, D.A., Sylvester, R.J., Tollemar, J., Viscoli, C., Viviani, M.A., and Wu, T. more...
- Abstract
Item does not contain fulltext, Studies of invasive fungal infections have been and remain difficult to implement. Randomized clinical trials of fungal infections are especially slow and expensive to perform because it is difficult to identify eligible patients in a timely fashion, to prove the presence of the fungal infection in an unequivocal fashion, and to evaluate outcome in a convincing fashion. Because of these challenges, licensing decisions for antifungal agents have to date depended heavily on historical control comparisons and secondary advantages of the new agent. Although the availability of newer and potentially more effective agents makes these approaches less desirable, the fundamental difficulties of trials of invasive fungal infections have not changed. Therefore, there is a need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses, and this article summarizes the possible strategies in this area. more...
- Published
- 2001
7. Identification of an amphotericin B resistant strain of Candida albicans using a rapid 3H-glucose incorporation microassay
- Author
-
Sweeney, J.F., primary, Greene, J.N., additional, Hiemenz, J.W., additional, Wei, S., additional, Rosemurgy, A.S., additional, and Djeu, J.Y., additional
- Published
- 1996
- Full Text
- View/download PDF
8. Aztreonam for febrile neutropenia in patients with beta-lactam allergy.
- Author
-
McCullough, B.J., Wiggins, L.E., Richards, A., Klinker, K., Hiemenz, J.W., and Wingard, J.R.
- Subjects
FEBRILE neutropenia ,DRUG side effects ,AZTREONAM ,ALLERGIES ,PENICILLIN ,CEPHALOSPORINS ,RETROSPECTIVE studies ,THERAPEUTICS - Abstract
Background Beta-lactam antibiotics are the mainstay of empiric therapy for febrile neutropenia. Aztreonam may benefit certain patients because of a lack of cross-hypersensitivity to penicillins and cephalosporins. This is the first study, to our knowledge, to evaluate the efficacy of aztreonam as monotherapy for febrile neutropenia ( FN). Methods Our study was a single-center retrospective chart review of patients ≥18 years of age receiving aztreonam for the treatment of FN. Primary outcome was treatment success of aztreonam monotherapy. Secondary analyses included need for modification to antimicrobial therapy, patients transitioned to aztreonam from another empiric regimen, and patients receiving aztreonam in combination with other antibacterial agents. Results In patients prescribed aztreonam for first fever, 11 of 27 (40.7%) patients who received aztreonam alone and 19 of 40 (47.5%) given aztreonam plus another antibiotic responded within 96 h ( P = 0.62). Twenty-four (89%) patients prescribed aztreonam monotherapy were alive when FN resolved or treatment ended. Infectious mortality was low (1 patient, 3.7%). In patients prescribed aztreonam monotherapy following an adverse reaction to cefepime, 6 of 11 (54.5%) responded within 96 h of initiating aztreonam; 10 (91%) were alive when FN resolved or treatment ended. Conclusion Aztreonam monotherapy may be acceptable for use in patients with a history of beta-lactam hypersensitivity or following an adverse reaction with another beta-lactam. Further studies are needed to compare efficacy of aztreonam monotherapy with other therapies for the treatment of FN. [ABSTRACT FROM AUTHOR] more...
- Published
- 2014
- Full Text
- View/download PDF
9. Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a Phase I/II study in breast cancer patients
- Author
-
Fields, K.K., primary, Perkins, J.P., additional, Hiemenz, J.W., additional, Zorsky, P.E., additional, Janssen, W.E., additional, Kronish, L.E., additional, Machak, M.C., additional, and Elfenbein, G.J., additional more...
- Published
- 1993
- Full Text
- View/download PDF
10. Invasive fusariosis associated with an injury by a stingray barb
- Author
-
Hiemenz, J.W., primary, Kennedy, B., additional, and Kwon-Chung, K.J., additional
- Published
- 1990
- Full Text
- View/download PDF
11. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency.
- Author
-
Ballester, O.F., Tummala, R., Janssen, W.E., Fields, K.K., Hiemenz, J.W., Goldstein, S.C., Perkins, J.B., Sullivan, D.M., Rosen, R., Sackstein, R., Zorsky, P., Saez, R., and Elfenbein, G.J.
- Subjects
MYELOMA proteins ,CHRONIC kidney failure ,DIALYSIS (Chemistry) ,STEM cells - Abstract
Six patients with multiple myeloma and chronic renal insufficiency (serum creatinine >3.0 mg/dl), including four on dialysis, received high-dose busulfan and cyclophosphamide (BUCY) followed by autologous peripheral stem cell transplantation. Peripheral blood stem cells were collected after priming with cyclophosphamide, etoposide and G-CSF. Patterns of engraftment and toxicities were not apparently different from those seen in myeloma patients with normal renal function. There was one toxicity-related death, resulting from a massive spontaneous subdural hematoma. One patient died of disease progression 6 months after transplant, while the remaining four patients are alive and free of myeloma progression 6 to 39 months after high-dose therapy. Two of these patients have remained in complete remission for 28 and 39 months. Our experience suggests that high-dose therapy with BUCY and autologous peripheral blood stem cell rescue is feasible in patients with multiple myeloma and renal failure. [ABSTRACT FROM AUTHOR] more...
- Published
- 1997
- Full Text
- View/download PDF
12. Invasive fusariosis associated with an injury by a stingray barb
- Author
-
Hiemenz, J.W., Kennedy, B., and Kwon-Chung, K.J.
- Abstract
A previously healthy adult male suffered a wound to the dorsal ulnar aspect of his right hand by a stingray barb while fishing off the East coast of Florida. Two weeks after the imbedded barb had been surgically removed, an erythematous lesion developed around the wound. Histopathologic and microbiological studies revealed infection caused by Fusarium solani. The patient was successfully treated with debridement and skin grafting in conjunction with ketoconazole therapy. more...
- Published
- 1990
- Full Text
- View/download PDF
13. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
- Author
-
Hani Hassoun, Jacob P. Laubach, Jan S. Moreb, Sara Thuresson, Paula Rodriguez-Otero, Marcus Thuresson, Michele Cavo, Albert Oriol, Maria-Victoria Mateos, Joan Bladé, John W. Hiemenz, Adrian Alegre, Amitabha Mazumder, Horizon (Op ) Investigators, Kenneth C. Anderson, Omar Nadeem, Johan Harmenberg, Nicolaas A Bakker, Xavier Leleu, Alessandra Larocca, Christopher Maisel, Paul G. Richardson, Agne Paner, Anastasios Raptis, Cyrille Touzeau, Catriona Byrne, Harvard Medical School [Boston] (HMS), Hospital Universitari Germans Trias I Pujol [Badalona], Università degli studi di Torino = University of Turin (UNITO), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), University of Bologna/Università di Bologna, Clínica Universidad de Navarra [Pamplona], Centre hospitalier universitaire de Poitiers (CHU Poitiers), University of Florida [Gainesville] (UF), Memorial Sloane Kettering Cancer Center [New York], Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université d'Angers (UA), Université de Nantes (UN), Site de Recherche Intégrée sur le Cancer [Nantes] (SIRIC), Centre hospitalier universitaire de Nantes (CHU Nantes), SIRIC ILIAD [Angers, Nantes], Hospital Universitario Quironsalud, Rush University Medical Center [Chicago], Baylor Scott & White Charles A. Sammons Cancer Center [Dallas, TX, USA], Oncology Institute of Hope and Innovation [Glendale, CA, USA] (OIHI), University of Pittsburgh School of Medicine, Pennsylvania Commonwealth System of Higher Education (PCSHE), Novant Health Forsyth Medical Center [Winston-Salem, NC, USA] (NHFMC), Oncopeptides AB [Stockholm, Sweden], Instituto de Investigación Biomédica de Salamanca [Salamanca, Spain] (IBSAL/CIC), HORIZON (OP-106) Investigators, Bernardo, Elizabeth, Università degli studi di Torino (UNITO), University of Bologna, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Richardson P.G., Oriol A., Larocca A., Blade J., Cavo M., Rodriguez-Otero P., Leleu X., Nadeem O., Hiemenz J.W., Hassoun H., Touzeau C., Alegre A., Paner A., Maisel C., Mazumder A., Raptis A., Moreb J.S., Anderson K.C., Laubach J.P., Thuresson S., Thuresson M., Byrne C., Harmenberg J., Bakker N.A., and Mateos M.-V. more...
- Subjects
Adult ,Male ,Cancer Research ,Time Factors ,Time Factor ,Phenylalanine ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Tumor cells ,Drug resistance ,Dexamethasone ,03 medical and health sciences ,0302 clinical medicine ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Recurrence ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Neoplasm ,Progression-free survival ,Melphalan ,Aged ,030304 developmental biology ,Aged, 80 and over ,0303 health sciences ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,Refractory Multiple Myeloma ,Middle Aged ,medicine.disease ,Progression-Free Survival ,United States ,3. Good health ,Europe ,Clinical trial ,Oncology ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Disease Progression ,Cancer research ,Female ,Multiple Myeloma ,business ,Human ,Conjugate ,medicine.drug - Abstract
PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a population with an important unmet medical need. PATIENTS AND METHODS Patients with RRMM refractory to pomalidomide and/or an anti-CD38 monoclonal antibody received melflufen 40 mg intravenously on day 1 of each 28-day cycle plus once weekly oral dexamethasone at a dose of 40 mg (20 mg in patients older than 75 years). The primary end point was overall response rate (partial response or better) assessed by the investigator and confirmed by independent review. Secondary end points included duration of response, progression-free survival, overall survival, and safety. The primary analysis is complete with long-term follow-up ongoing. RESULTS Of 157 patients (median age 65 years; median five prior lines of therapy) enrolled and treated, 119 patients (76%) had triple-class–refractory disease, 55 (35%) had extramedullary disease, and 92 (59%) were refractory to previous alkylator therapy. The overall response rate was 29% in the all-treated population, with 26% in the triple-class–refractory population. In the all-treated population, median duration of response was 5.5 months, median progression-free survival was 4.2 months, and median overall survival was 11.6 months at a median follow-up of 14 months. Grade ≥ 3 treatment-emergent adverse events occurred in 96% of patients, most commonly neutropenia (79%), thrombocytopenia (76%), and anemia (43%). Pneumonia (10%) was the most common grade 3/4 nonhematologic event. Thrombocytopenia and bleeding (both grade 3/4 but fully reversible) occurred concomitantly in four patients. GI events, reported in 97 patients (62%), were predominantly grade 1/2 (93%); none were grade 4. CONCLUSION Melflufen plus dexamethasone showed clinically meaningful efficacy and a manageable safety profile in patients with heavily pretreated RRMM, including those with triple-class–refractory and extramedullary disease. more...
- Published
- 2021
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.